Communication drivers for drug adoption in an uncertain world

Abstract

Purpose The quality and reliability of medical communication for branded drug adoption is extremely critical, not only for safeguarding patient interests but also for ensuring successful investments by multinational pharmaceutical firms. This paper predicts doctors’ prescribing intentions based on communication relationship among factors for late entrant branded drugs, compared with pioneering brand choice, for treating chronic diseases such as hypertension. Design/methodology/approach The constructs were validated with structural equation model for a sample set of 151 doctors from private hospitals in the National Capital Region of India. Findings This research reveals communication drivers and draws on theory to suggest that the doctor’s behavioural prescription intentions, subject to social influence from their colleagues, leads to lower adoption responses. Research limitations/implications Given that limitations on sample size are often unavoidable, this study reveals that, due to the availability of substituting brands, alternate therapeutic routes and lack of availability of a practical guide for prescription, a communication model needs to be developed and validated. Practical implications Furthermore, managers of pharmaceutical firms should differentiate between the effects of direct and indirect communication–integration efforts for minimizing uncertainty in drug adoption in the context of the fragmented and unpredictable Indian market. Originality/value A late entrant may lose its dominant market share to alternate brands from other suppliers due to communication gaps in an unstructured market, leading to low adoption intentions. The study provides business theorists, drug marketers and health-care professionals with unique insights into specific communication drivers of prescribing decisions, aimed at ensuring reliable and appropriate drug adoption in Indian markets.

Influence of Collaborative Planning on Performance of Pharmaceutical Firms in Kenya

“…According to Porter and Lee (2013), Pharmaceutical chains and relationships are centered on competing branded medicines and exposed to complex interactions between various players such as government bodies, health-care providers and manufacturing firms (Goswami et al, 2016).In the past, pharmaceutical firms did not adopt supply chain management concepts but today several factors are pressing pharmaceutical firms to change their traditional manners of conducting business (Ahmad et al, 2012). This supply chain is more complex and different from other industry supply chains as it handles a diversity of items in widely varying quantities in response to the large number of diagnosis types and procedures (AbuKhousa et al, 2014), and also because it requires the participation of different stakeholders such as pharmaceutical manufacturers, wholesalers, In Kenya most pharmaceutical firms act as distributors importing directly from manufacturers overseas, arrange shipment of goods from country of origin and customs clearance and handle the domestic sales of the products (Chopra & Meindl, 2013).…”

The Effects of Process Alignment on Performance of Pharmaceutical Firms in Kenya

“…Pharmaceutical chains and relationships are centered on competing branded medicines and are exposed to complex interactions between various players such as government bodies, health-care providers and manufacturing firms (Goswami et al, 2016). In the past, pharmaceutical firms did not adopt supply chain management concepts but today several factors are forcing pharmaceutical firms to change their traditional manners of conducting business (Ahmad et al, 2012).…”